These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 18566448)

  • 1. Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis.
    Beum PV; Lindorfer MA; Beurskens F; Stukenberg PT; Lokhorst HM; Pawluczkowycz AW; Parren PW; van de Winkel JG; Taylor RP
    J Immunol; 2008 Jul; 181(1):822-32. PubMed ID: 18566448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Penetration of antibody-opsonized cells by the membrane attack complex of complement promotes Ca(2+) influx and induces streamers.
    Beum PV; Lindorfer MA; Peek EM; Stukenberg PT; de Weers M; Beurskens FJ; Parren PW; van de Winkel JG; Taylor RP
    Eur J Immunol; 2011 Aug; 41(8):2436-46. PubMed ID: 21674476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX.
    Pawluczkowycz AW; Beurskens FJ; Beum PV; Lindorfer MA; van de Winkel JG; Parren PW; Taylor RP
    J Immunol; 2009 Jul; 183(1):749-58. PubMed ID: 19535640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab.
    Kennedy AD; Solga MD; Schuman TA; Chi AW; Lindorfer MA; Sutherland WM; Foley PL; Taylor RP
    Blood; 2003 Feb; 101(3):1071-9. PubMed ID: 12393727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative analysis of protein co-localization on B cells opsonized with rituximab and complement using the ImageStream multispectral imaging flow cytometer.
    Beum PV; Lindorfer MA; Hall BE; George TC; Frost K; Morrissey PJ; Taylor RP
    J Immunol Methods; 2006 Dec; 317(1-2):90-9. PubMed ID: 17067631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complement activation and C3b deposition on rituximab-opsonized cells substantially blocks binding of phycoerythrin-labeled anti-mouse IgG probes to rituximab.
    Beum PV; Kennedy AD; Li Y; Pawluczkowycz AW; Williams ME; Taylor RP
    J Immunol Methods; 2004 Nov; 294(1-2):37-42. PubMed ID: 15604014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia.
    Kennedy AD; Beum PV; Solga MD; DiLillo DJ; Lindorfer MA; Hess CE; Densmore JJ; Williams ME; Taylor RP
    J Immunol; 2004 Mar; 172(5):3280-8. PubMed ID: 14978136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving.
    Beum PV; Lindorfer MA; Taylor RP
    J Immunol; 2008 Aug; 181(4):2916-24. PubMed ID: 18684983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complement-Dependent Activity of CD20-Specific IgG Correlates With Bivalent Antigen Binding and C1q Binding Strength.
    Bondza S; Marosan A; Kara S; Lösing J; Peipp M; Nimmerjahn F; Buijs J; Lux A
    Front Immunol; 2020; 11():609941. PubMed ID: 33505398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy.
    Bologna L; Gotti E; Da Roit F; Intermesoli T; Rambaldi A; Introna M; Golay J
    J Immunol; 2013 Jan; 190(1):231-9. PubMed ID: 23225880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions.
    Cook EM; Lindorfer MA; van der Horst H; Oostindie S; Beurskens FJ; Schuurman J; Zent CS; Burack R; Parren PW; Taylor RP
    J Immunol; 2016 Sep; 197(5):1762-75. PubMed ID: 27474078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct in vitro sensitivity of p53-mutated and ATM-mutated chronic lymphocytic leukemia cells to ofatumumab and rituximab.
    Sebejova L; Borsky M; Jaskova Z; Potesil D; Navrkalova V; Malcikova J; Sramek M; Doubek M; Loja T; Pospisilova S; Mayer J; Trbusek M
    Exp Hematol; 2014 Oct; 42(10):867-74.e1. PubMed ID: 24970561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-time analysis of the detailed sequence of cellular events in mAb-mediated complement-dependent cytotoxicity of B-cell lines and of chronic lymphocytic leukemia B-cells.
    Lindorfer MA; Cook EM; Tupitza JC; Zent CS; Burack R; de Jong RN; Beurskens FJ; Schuurman J; Parren PW; Taylor RP
    Mol Immunol; 2016 Feb; 70():13-23. PubMed ID: 26690706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HuMab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20 can effectively eliminate CD20 low expressing tumor cells that resist rituximab-mediated lysis.
    van Meerten T; Rozemuller H; Hol S; Moerer P; Zwart M; Hagenbeek A; Mackus WJ; Parren PW; van de Winkel JG; Ebeling SB; Martens AC
    Haematologica; 2010 Dec; 95(12):2063-71. PubMed ID: 20851867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes.
    Beum PV; Mack DA; Pawluczkowycz AW; Lindorfer MA; Taylor RP
    J Immunol; 2008 Dec; 181(11):8120-32. PubMed ID: 19018005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas.
    Teeling JL; French RR; Cragg MS; van den Brakel J; Pluyter M; Huang H; Chan C; Parren PW; Hack CE; Dechant M; Valerius T; van de Winkel JG; Glennie MJ
    Blood; 2004 Sep; 104(6):1793-800. PubMed ID: 15172969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells.
    Beum PV; Peek EM; Lindorfer MA; Beurskens FJ; Engelberts PJ; Parren PW; van de Winkel JG; Taylor RP
    J Immunol; 2011 Sep; 187(6):3438-47. PubMed ID: 21841127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression and biological characterization of an anti-CD20 biosimilar candidate antibody: a case study.
    Dorvignit D; Palacios JL; Merino M; Hernández T; Sosa K; Casaco A; López-Requena A; Mateo de Acosta C
    MAbs; 2012; 4(4):488-96. PubMed ID: 22647435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations resulting in the formation of hyperactive complement convertases support cytocidal effect of anti-CD20 immunotherapeutics.
    Felberg A; Urban A; Borowska A; Stasiłojć G; Taszner M; Hellmann A; Blom AM; Okrój M
    Cancer Immunol Immunother; 2019 Apr; 68(4):587-598. PubMed ID: 30725204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia.
    Williams ME; Densmore JJ; Pawluczkowycz AW; Beum PV; Kennedy AD; Lindorfer MA; Hamil SH; Eggleton JC; Taylor RP
    J Immunol; 2006 Nov; 177(10):7435-43. PubMed ID: 17082663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.